Publications
-
Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas.
Chang DT,
Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, Ford JM, Desser T, Quon A, Koong AC.
Cancer.
2009;
115
(3):
665-72
-
Multimodality treatment with intensity modulated radiation therapy for esophageal cancer.
La TH,
Minn AY, Su Z, Fisher GA, Ford JM, Kunz P, Goodman KA, Koong AC, Chang DT.
Dis Esophagus.
2009
-
Impaired interferon signaling is a common immune defect in human cancer.
Critchley-Thorne RJ,
Simons DL, Yan N, Miyahira AK, Dirbas FM, Johnson DL, Swetter SM, Carlson RW, Fisher GA, Koong A, Holmes S, Lee PP.
Proc Natl Acad Sci U S A.
2009;
106
(22):
9010-5
-
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.
Wakelee HA,
Patnaik A, Sikic BI, Mita M, Fox NL, Miceli R, Ullrich SJ, Fisher GA, Tolcher AW.
Ann Oncol.
2009
-
Pathological Response after Chemoradiation for T3 Rectal Cancer.
Chennupati SK,
Kamaya A, Fisher GA, Ford JM, Kunz P, Itakura H, Welton ML, Shelton A, Van Dam J, Koong AC, Chang DT.
Colorectal Dis.
2009
-
Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.
Schellenberg D,
Goodman KA, Lee F, Chang S, Kuo T, Ford JM, Fisher GA, Quon A, Desser TS, Norton J, Greco R, Yang GP, Koong AC.
Int J Radiat Oncol Biol Phys.
2008;
72
(3):
678-86
-
Tissue effects after stereotactic body radiotherapy using cyberknife for patients with abdominal malignancies.
Cupp JS,
Koong AC, Fisher GA, Norton JA, Goodman KA.
Clin Oncol (R Coll Radiol).
2008;
20
(1):
69-75
-
Phase II study of imatinib in unresectable hepatocellular carcinoma.
Lin AY,
Fisher GA, So S, Tang C, Levitt L.
Am J Clin Oncol.
2008;
31
(1):
84-8
-
A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer.
Fisher GA,
Kuo T, Ramsey M, Schwartz E, Rouse RV, Cho CD, Halsey J, Sikic BI.
Clin Cancer Res.
2008;
14
(21):
7074-9
-
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate.
Telli ML,
Witteles RM, Fisher GA, Srinivas S.
Ann Oncol.
2008;
19
(9):
1613-8
-
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
Demetri GD,
Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J.
J Natl Compr Canc Netw.
2007:
5 Suppl 2
S1-29; quiz S30
-
Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer.
Cabebe E,
Fisher GA.
Expert Opin Investig Drugs.
2007;
16
(4):
467-76
-
Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies.
Cho CD,
Fisher GA, Halsey J, Sikic BI.
Invest New Drugs.
2006;
24
(2):
117-23
-
Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer.
Street HH,
Goris ML, Fisher GA, Wessels BW, Cho C, Hernandez C, Zhu HJ, Zhang Y, Nangiana JS, Shan JS, Roberts K, Knox SJ.
Cancer Biother Radiopharm.
2006;
21
(3):
243-56
-
Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma.
Lin AY,
Brophy N, Fisher GA, So S, Biggs C, Yock TI, Levitt L.
Cancer.
2005;
103
(1):
119-25
-
A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer.
Wakelee H,
Fisher GA.
Invest New Drugs.
2005;
23
(3):
241-2
-
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.
Koong AC,
Christofferson E, Le QT, Goodman KA, Ho A, Kuo T, Ford JM, Fisher GA, Greco R, Norton J, Yang GP.
Int J Radiat Oncol Biol Phys.
2005;
63
(2):
320-3
-
Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer.
Kuo T,
Fisher GA.
Clin Colorectal Cancer.
2005:
5 Suppl 2
S62-70
-
A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance.
Advani R,
Lum BL, Fisher GA, Halsey J, Chin DL, Jacobs CD, Sikic BI.
Ann Oncol.
2005;
16
(12):
1968-73
-
A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer.
Advani R,
Lum BL, Fisher GA, Halsey J, Geary RS, Holmlund JT, Kwoh TJ, Dorr FA, Sikic BI.
Invest New Drugs.
2005;
23
(5):
467-77
-
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
Kuo T,
Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI.
J Clin Oncol.
2005;
23
(24):
5613-9
-
Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer.
Koong AC,
Le QT, Ho A, Fong B, Fisher G, Cho C, Ford J, Poen J, Gibbs IC, Mehta VK, Kee S, Trueblood W, Yang G, Bastidas JA.
Int J Radiat Oncol Biol Phys.
2004;
58
(4):
1017-21
-
A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.
Advani R,
Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ, Halsey J, Holmlund JT, Dorr A, Sikic BI.
Cancer.
2004;
100
(2):
321-6
-
Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.
Advani R,
Fisher GA, Lum BL, Jambalos C, Cho CD, Cohen M, Gollerkeri A, Sikic BI.
Clin Cancer Res.
2003;
9
(14):
5187-94
-
Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer.
Mehta VK,
Cho C, Ford JM, Jambalos C, Poen J, Koong A, Lin A, Bastidas JA, Young H, Dunphy EP, Fisher G.
Int J Radiat Oncol Biol Phys.
2003;
55
(1):
132-7
-
Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas.
Mehta VK,
Fisher G, Ford JA, Poen JC, Vierra MA, Oberhelman H, Niederhuber J, Bastidas JA.
J Gastrointest Surg.
2001 Jan-Feb;
5
(1):
27-35
-
Center experience in liver transplantation for hepatocellular carcinoma associated with cirrhosis.
Lai KM,
Millan M, Razavi M, Keeffe EB, Prapong W, Fisher GA, Esquivel CO, So SK.
Transplant Proc.
2001 Feb-Mar;
33
(1-2):
1490-1
-
A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.
Advani R,
Fisher GA, Lum BL, Hausdorff J, Halsey J, Litchman M, Sikic BI.
Clin Cancer Res.
2001;
7
(5):
1221-9
-
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy.
Fong L,
Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG.
Proc Natl Acad Sci U S A.
2001;
98
(15):
8809-14
-
Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer.
Mehta VK,
Poen J, Ford J, Edelstein PS, Vierra M, Bastidas AJ, Young H, Fisher G.
Dis Colon Rectum.
2001;
44
(1):
52-8
-
Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer.
Mehta VK,
Poen JC, Ford JM, Oberhelman HA, Vierra MA, Bastidas AJ, Fisher GA.
Am J Clin Oncol.
2001;
24
(2):
155-9
-
Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of Vater: preliminary report.
Mehta VK,
Fisher GA, Ford JM, Poen JC, Vierra MA, Oberhelman HA, Bastidas AJ.
Arch Surg.
2001;
136
(1):
65-9
-
Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer.
Mehta VK,
Fisher GA, Ford JM, Oberhelman HA, Vierra MA, Bastidas AJ, Poen JC.
Int J Radiat Oncol Biol Phys.
2000;
48
(5):
1483-7
-
Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
Lum BL,
Kaubisch S, Fisher GA, Brown BW, Sikic BI.
Cancer Chemother Pharmacol.
2000;
45
(4):
305-11
-
Pancreatic tumors show high levels of hypoxia.
Koong AC,
Mehta VK, Le QT, Fisher GA, Terris DJ, Brown JM, Bastidas AJ, Vierra M.
Int J Radiat Oncol Biol Phys.
2000;
48
(4):
919-22
-
Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer.
Yuen AR,
Halsey J, Fisher GA, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Sikic BI.
Clin Cancer Res.
1999;
5
(11):
3357-63
-
Chemo-radiotherapy for localized pancreatic cancer: increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil.
Poen JC,
Collins HL, Niederhuber JE, Oberhelman HA, Vierra MA, Bastidas AJ, Young HS, Slosberg EA, Jeffrey BR, Longacre TA, Fisher GA, Goffinet DR.
Int J Radiat Oncol Biol Phys.
1998;
40
(1):
93-9
-
Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI,
Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G.
Cancer Chemother Pharmacol.
1997:
40 Suppl
S13-9
-
Pharmacological considerations in the modulation of multidrug resistance.
Fisher GA,
Lum BL, Hausdorff J, Sikic BI.
Eur J Cancer.
1996;
32A
(6):
1082-8
-
Clinical studies with modulators of multidrug resistance.
Fisher GA,
Sikic BI.
Hematol Oncol Clin North Am.
1995;
9
(2):
363-82
-
Drug resistance in clinical oncology and hematology. Introduction.
Fisher GA,
Sikic BI.
Hematol Oncol Clin North Am.
1995;
9
(2):
xi-xii
-
The reversal of multidrug resistance.
Fisher GA,
Lum BL, Sikic BI.
Cancer Treat Res.
1995:
78
45-70
-
Mammalian cell survival studies characterizing multiport negative pi-meson irradiation with the Stanford Medical Pion Generator (SMPG).
Li GC,
Fessenden P, Hahn GM, Fisher G, Luxton G, Bagshaw MA.
Int J Hyperthermia.
1994 May-Jun;
10
(3):
361-70
-
Clinical reversal of multidrug resistance.
Sikic BI,
Fisher GA, Lum BL, Brophy NA, Yahanda AM, Adler KM, Halsey J.
Cancer Treat Res.
1994:
73
149-65
-
Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.
Bartlett NL,
Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI.
J Clin Oncol.
1994;
12
(4):
835-42
-
Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations.
Lum BL,
Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J, Sikic BI.
Cancer.
1993;
72
(11 Suppl):
3502-14
-
Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.
Yahanda AM,
Alder KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, Sikic BI.
J Clin Oncol.
1992;
10
(10):
1624-34
-
DNA damage does not appear to be a trigger for thermotolerance in mammalian cells.
Anderson RL,
Shiu E, Fisher GA, Hahn GM.
Int J Radiat Biol.
1988;
54
(2):
285-98
-
Correlation of mammalian cell killing by heat shock to intramembranous particle aggregation and lateral phase separation using fluorescence-activated cell sorting.
Rice GC,
Fisher KA, Fisher GA, Hahn GM.
Radiat Res.
1987;
112
(2):
351-64
Help